A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs NYX-783 (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors Aptinyx
- 12 Aug 2019 According to an Aptinyx media release, completion and reporting top-line data from this study is expected in 2H2020.
- 14 May 2019 According to an Aptinyx media release, trial completion expected in 1H 2020.
- 19 Feb 2019 According to an Aptinyx media release, first patient has been dosed in the study. The company expects to report data from this study in the first half of 2020.